DOI QR코드

DOI QR Code

Efficacy and Safety of Concomitant Chemoradiotherapy with Cisplatin and Docetaxel in Patients with Locally Advanced Squamous Cell Head and Neck Cancers

  • Baykara, Meltem (Department of Medical Oncology, Sakarya University Training and Research Hospital) ;
  • Buyukberber, Suleyman (Department of Medical Oncology, Gazi University Medical Faculty) ;
  • Ozturk, Banu (Gaziosmanpasa University Medical Faculty, Department of Medical Oncology) ;
  • Coskun, Ugur (Department of Medical Oncology, Gazi University Medical Faculty) ;
  • Unsal, Diclehan Kilic (Department of Radiation Oncology, Gazi University Medical Faculty) ;
  • Demirci, Umut (Department of Medical Oncology, Ankara Ataturk Training and Research Hospital) ;
  • Dane, Faysal (Department of Medical Oncology, Marmara University Medical Faculty) ;
  • Kaplan, Muhammet Ali (Department of Medical Oncology, Dicle University Medical Faculty) ;
  • Bora, Huseyin (Department of Radiation Oncology, Gazi University Medical Faculty) ;
  • Benekli, Mustafa (Department of Medical Oncology, Gazi University Medical Faculty)
  • 발행 : 2013.04.30

초록

Background: Chemoradiation (CRT) using cisplatin-based regimens has become the standard of care in the treatment of squamous cell head and neck cancers (SCHNC). The impact of taxanes as radiosensitizing agents with concurrent CRT regimens is unknown. We therefore retrospectively evaluated the efficacy and tolerability of a weekly cisplatin+docetaxel combination with CRT in locally advanced SCHNC. Methods: Sixty-six patients with locally advanced SCHNC (39.4% stage IV, 53% stage III, and 7.6% stage II) were assessed retrospectively. Total radiation dose to the PTV of gross disease (primary and/or node) was 70 Gy/35 fractions, 5 fractions per week. Minimum doses of 60 Gy and 50 Gy were administered to PTVs of elective high risk and low risk disease, respectively. Chemotherapy (CT) consisted of weekly cisplatin (20 $mg/m^2$)+docetaxel (20 $mg/m^2$) concurrently with RT. Results: The median age of the patients was 58 years (range, 32-77). Objective response rate was 83.3%. The 2-year progression-free survival (PFS) and overall survival (OS) were 75.7% and 78.3%, respectively. The most common grade 3 and 4 toxicities were mucositis (36.4%), nausea and vomiting (12.1%), neutropenia (4.5%). Conclusion: Weekly cisplatin and docetaxel concurrent with RT for locally advanced SCHNC was found tolerable with high efficacy.

참고문헌

  1. Adelstein DJ, Li Y, Adams GL, et al (2003). An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol, 21, 92-8. https://doi.org/10.1200/JCO.2003.01.008
  2. Adelstein DJ, Lavertu P, Saxton JP, et al (2000). Mature results of a phase III randomized trial comparing concurrent chemoradiotherapy with radiation therapy alone in patients with stage III and IV squamous cell carcinoma of the head and neck. Cancer, 88, 876-83. https://doi.org/10.1002/(SICI)1097-0142(20000215)88:4<876::AID-CNCR19>3.0.CO;2-Y
  3. Agarwala SS, Cano E, Heron DE, et al (2007). Long-term outcomes with concurrent carboplatin, paclitaxel and radiation therapy for locally advanced, inoperable head and neck cancer. Ann Oncol, 18, 1224-9. https://doi.org/10.1093/annonc/mdm088
  4. Bernier J, Schneider D (2007). Cetuximab combined with radiotherapy: an alternative to chemoradiotherapy for patients with locally advanced squamous cell carcinomas of the head and neck? Eur J Cancer, 43, 35-45. https://doi.org/10.1016/j.ejca.2006.08.035
  5. Bourhis J, Lefebvre JL, Vermorken JB (2010). Cetuximab in the management of locoregionally advanced head and neck cancer: expanding the treatment options? Eur J Cancer , 46, 1979-89. https://doi.org/10.1016/j.ejca.2010.05.015
  6. Bourhis J, Le Maître A, Baujat B, Audry H, Pignon JP (2007). Meta-analysis of chemotherapy in head, neck cancer collaborative group; meta-analysis of radiotherapy in carcinoma of head, neck collaborative group; meta-analysis of chemotherapy in nasopharynx carcinoma collaborative group. individual patients' data meta-analyses in head and neck cancer. Curr Opin Oncol, 19,188-94 https://doi.org/10.1097/CCO.0b013e3280f01010
  7. Brizel DM, Albers ME, Fisher SR, et al (1998). Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med, 338, 1798-804. https://doi.org/10.1056/NEJM199806183382503
  8. Calais G, Alfonsi M, Bardet E, et al (1999). Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst, 91, 2081-6. https://doi.org/10.1093/jnci/91.24.2081
  9. Chitapanarux I, Lorvidhaya V, Tharavichitkul E, (2011). A phase II study of docetaxel and carboplatin with concurrent radiation therapy for locally advanced head and neck cancer. Auris Nasus Larynx, 38, 108-13. https://doi.org/10.1016/j.anl.2010.05.012
  10. Chougule PB, Akhtar MS, Rathore R, et al (2008). Concurrent chemoradiotherapy with weekly paclitaxel and carboplatin for locally advanced head and neck cancer: Long-term follow-up of a Brown University Oncology Group Phase II Study (HN-53). Head Neck, 30, 289-96. https://doi.org/10.1002/hed.20700
  11. Cmelak AJ, Li S, Goldwasser MA, et al (2007). Phase II trial of chemoradiation for organ preservation in resectable stage III or IV squamous cell carcinomas of the larynx or oropharynx: results of Eastern Cooperative Oncology Group Study E2399. J Clin Oncol, 25,3971-7. https://doi.org/10.1200/JCO.2007.10.8951
  12. D'Souza G, Kreimer AR, Viscidi R, et al (2007). Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med, 356, 1944-56. https://doi.org/10.1056/NEJMoa065497
  13. Forastiere AA, Zhang Q, Weber RS, et al (2013). Long-Term Results of RTOG 91-11: A Comparison of Three Nonsurgical Treatment Strategies to Preserve the Larynx in Patients With Locally Advanced Larynx Cancer. J Clin Oncol, 31, 845-52. https://doi.org/10.1200/JCO.2012.43.6097
  14. Forastiere AA, Goepfert H, Maor M, et al (2003). Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med, 349, 2091-8. https://doi.org/10.1056/NEJMoa031317
  15. Fornari G, Artusio E, Mairone L, et al (2002). Paclitaxel and carboplatin in neo-adjuvant and concomitant chemoradiotherapy in locally advanced head and neck squamous cell carcinoma. Tumori, 88, 489-94.
  16. Garden AS, Harris J, Vokes EE, et al (2004). Preliminary results of Radiation Therapy Oncology Group 97-03: a randomized phase ii trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck. J Clin Oncol, 22, 2856-64. https://doi.org/10.1200/JCO.2004.12.012
  17. Haddad R, O'Neill A, Rabinowits G, et al (2013). Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. Lancet Oncol, 14, 257-64. https://doi.org/10.1016/S1470-2045(13)70011-1
  18. Huang J, Baschnagel AM, Chen P, et al (2007). A matched-pair comparison of intensity-modulated radiation therapy with cetuximab versus intensity-modulated radiation therapy with platinum-based chemotherapy for locally advanced head neck cancer. Int J Clin Oncol, 10, 0540.
  19. Jemal A, Siegel R, Xu J, Ward E (2010). Cancer statistics. CA Cancer J Clin, 60, 277-300. https://doi.org/10.3322/caac.20073
  20. Jeremic B, Shibamoto Y, Milicic B, et al (2000). Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial. J Clin Oncol, 18, 1458-64.
  21. Karasawa K, Shinoda H, Katsui K, et al (2002). Radiotherapy with concurrent docetaxel and carboplatin for head and neck cancer. Anticancer Res. 22, 3785-8.
  22. Krengli M, Masini L, Gambaro G, et al (2001). Concurrent chemotherapy with carboplatin + 5-fluorouracil and radiotherapy in advanced squamous cell head and neck carcinoma: a retrospective single institution's study. Tumori, 86, 312-6.
  23. Landis SH, Murray T, Bolden S, Wingo PA (1999). Cancer Statistics, 1999. CA Cancer J Clin, 49, 8-31. https://doi.org/10.3322/canjclin.49.1.8
  24. Matsumoto F, Karasawa K, Itoh S, et al (2006). Concurrent weekly docetaxel and hyperfractionated radiotherapy for advanced head and neck cancer. Anticancer Res, 26, 3781-6.
  25. Mauer AM, Masters GA, Haraf DJ, et al (1998). Phase I study of docetaxel with concomitant thoracic radiation therapy. J Clin Oncol, 16, 159-64.
  26. Mencoboni M, Grillo-Ruggieri F, Salami A, et al (2011). Induction chemotherapy in head and neck cancer patients followed by concomitant docetaxel-based radiochemotherapy. Eur J Cancer Care, 20, 503-7. https://doi.org/10.1111/j.1365-2354.2010.01185.x
  27. Mencoboni M, Rebella L, Tredici S, et al (2005). Concurrent chemo-radiotherapy with taxotere and cisplatin in head and neck cancer: a feasibility study. Anticancer Res, 25, 4451-4.
  28. Okami K, Hamano T, Takeo T, et al (2008). Concurrent chemoradiotherapy with docetaxel for T2 laryngeal carcinoma. Tokai J Exp Clin Med, 33, 130-4.
  29. Pignon JP, le Maître A, Bourhis J (2007) MACH-NC Collaborative Group. Meta-Analyses of Chemotherapy in Head and Neck Cancer (MACH-NC): an update. Int J Radiat Oncol Biol Phys, 69, 112-4
  30. Pignon JP, Bourhis J, Domenge J, Designe L, MACH-NC (2000). Collaborative Group. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. Meta-analysis of chemotherapy on head and neck cancer. Lancet, 355, 949-55. https://doi.org/10.1016/S0140-6736(00)90011-4
  31. Ready NE, Rathore R, Johnson TT, et al (2012). Weekly Paclitaxel and Carboplatin Induction Chemotherapy Followed by Concurrent Chemoradiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck. Am J Clin Oncol, 35, 6-12. https://doi.org/10.1097/COC.0b013e3182019ee3
  32. Schwartz DL, Montgomery RB, Yueh B, et al (2005). Phase I and initial phase II results from a trial investigating weekly docetaxel and carboplatin given neoadjuvantly and then concurrently with concomitant boost radiotherapy for locally advanced squamous cell carcinoma of the head and neck. Cancer, 103, 2534-43. https://doi.org/10.1002/cncr.21085
  33. Suzuki M, Nishimura Y, Nakamatsu K, et al (2003). Phase I study of weekly docetaxel infusion and concurrent radiation therapy for head and neck cancer. Jpn J Clin Oncol, 33, 297-301. https://doi.org/10.1093/jjco/hyg054
  34. Tishler RB, Norris CM Jr, Colevas AD, et al (2002). A Phase I/ II trial of concurrent docetaxel and radiation after induction chemotherapy in patients with poor prognosis squamous cell carcinoma of the head and neck. Cancer, 95, 1472-81. https://doi.org/10.1002/cncr.10873
  35. Tishler RB, Posner MR, Norris CM Jr, et al (2006). Concurrent weekly docetaxel and concomitant boost radiation therapy in the treatment of locally advanced squamous cell cancer of the head and neck. Int J Radiat Oncol Biol Phys, 65, 1036-1044. https://doi.org/10.1016/j.ijrobp.2006.02.010
  36. Tsao AS, Garden AS, Kies MS, et al (2006). Phase I/II study of docetaxel, cisplatin, and concomitant boost radiation for locally advanced squamous cell cancer of the head and neck. J Clin Oncol, 24, 4163-9. https://doi.org/10.1200/JCO.2006.05.7851
  37. Okami K, Hamano T, Takeo T, et al (2008). Concurrent chemoradiotherapy with docetaxel for T2 laryngeal carcinoma. Tokai J Exp Clin Med, 33, 130-4.
  38. Tsao AS, Garden AS, Kies MS, et al (2006). Phase I/II study of docetaxel, cisplatin, and concomitant boost radiation for locally advanced squamous cell cancer of the head and neck. J Clin Oncol, 24, 4163-9. https://doi.org/10.1200/JCO.2006.05.7851
  39. Wendt TG, Grabenbauer GG, Rodel CM, et al (1998). Schalhorn A. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. J Clin Oncol, 16, 1318-24.

피인용 문헌

  1. Role of Concomitant Chemoradiation in Locally Advanced Head and Neck Cancers vol.15, pp.10, 2014, https://doi.org/10.7314/APJCP.2014.15.10.4147
  2. Novel DOX-MTX Nanoparticles Improve Oral SCC Clinical Outcome by Down Regulation of Lymph Dissemination Factor VEGF-C Expression in vivo: Oral and IV Modalities vol.15, pp.15, 2014, https://doi.org/10.7314/APJCP.2014.15.15.6227
  3. Comparison of Radical Cystectomy and Chemoradiotherapy in Patients with Locally Advanced Bladder Cancer vol.15, pp.16, 2014, https://doi.org/10.7314/APJCP.2014.15.16.6519
  4. DOX-MTX-NPs Augment p53 mRNA Expression in OSCC Model in Rat: Effects of IV and Oral Routes vol.15, pp.19, 2014, https://doi.org/10.7314/APJCP.2014.15.19.8377
  5. New formulated "DOX-MTX-loaded Nanoparticles" Down-regulate HER2 Gene Expression and Improve the Clinical Outcome in OSCCs Model in Rat: the Effect of IV and Oral Modalities vol.15, pp.21, 2014, https://doi.org/10.7314/APJCP.2014.15.21.9355
  6. Phase II Study on EANI Combined with Hydrochloride Palonosetron for Prevention of Chemotherapy-induced Nausea and Vomiting Following Highly Emetogenic Chemotherapy vol.15, pp.9, 2014, https://doi.org/10.7314/APJCP.2014.15.9.3951
  7. Oral and IV Dosages of Doxorubicin-Methotrexate loaded-Nanoparticles Inhibit Progression of Oral Cancer by Down-Regulation of Matrix Methaloproteinase 2 Expression in Vivo vol.15, pp.24, 2015, https://doi.org/10.7314/APJCP.2014.15.24.10705
  8. Weekly Cisplatin-Based Concurrent Chemoradiotherapy for Treatment of Locally Advanced Head and Neck Cancer: a Single Institution Study vol.16, pp.16, 2015, https://doi.org/10.7314/APJCP.2015.16.16.7309
  9. Concurrent Chemoradiation with Weekly Cisplatin for the Treatment of Head and Neck Cancers: an Institutional Study on Acute Toxicity and Response to Treatment vol.16, pp.16, 2015, https://doi.org/10.7314/APJCP.2015.16.16.7331
  10. Survival in Head and Neck Cancers - Results of A Multi-Institution Study vol.17, pp.4, 2016, https://doi.org/10.7314/APJCP.2016.17.4.1745